CN101028322B - Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases - Google Patents
Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases Download PDFInfo
- Publication number
- CN101028322B CN101028322B CN2007100389611A CN200710038961A CN101028322B CN 101028322 B CN101028322 B CN 101028322B CN 2007100389611 A CN2007100389611 A CN 2007100389611A CN 200710038961 A CN200710038961 A CN 200710038961A CN 101028322 B CN101028322 B CN 101028322B
- Authority
- CN
- China
- Prior art keywords
- butterbur
- extract
- cancer
- pilaris
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title claims description 10
- 240000003296 Petasites japonicus Species 0.000 title abstract description 52
- 206010028980 Neoplasm Diseases 0.000 title abstract description 11
- 235000003823 Petasites japonicus Nutrition 0.000 title description 51
- 235000001436 butterbur Nutrition 0.000 title description 51
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 6
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims abstract description 4
- 201000002313 intestinal cancer Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 241001113309 Petasites tricholobus Species 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 abstract description 7
- 208000014018 liver neoplasm Diseases 0.000 abstract description 7
- 235000019537 butterbur extract Nutrition 0.000 abstract description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 5
- 201000010982 kidney cancer Diseases 0.000 abstract description 5
- 201000005202 lung cancer Diseases 0.000 abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 abstract description 5
- NRUNMIDOAAWGBJ-UHFFFAOYSA-N Bakkenolide D Natural products CC1CCC(OC(=O)C=C/CS)C2C(OC(=O)C)C3(CC12C)C(=C)COC3=O NRUNMIDOAAWGBJ-UHFFFAOYSA-N 0.000 abstract description 2
- LWHLMCCRIWZBQO-PDSBHGERSA-N [(2R,3R,3aR,4S,7S,7aR)-3-acetyloxy-7,7a-dimethyl-4'-methylidene-2'-oxospiro[3,3a,4,5,6,7-hexahydro-1H-indene-2,3'-oxolane]-4-yl] (Z)-3-methylsulfanylprop-2-enoate Chemical compound S(/C=C\C(=O)O[C@@H]1[C@@H]2[C@@H](OC(=O)C)[C@@]3(C(=O)OCC3=C)C[C@]2(C)[C@@H](C)CC1)C LWHLMCCRIWZBQO-PDSBHGERSA-N 0.000 abstract description 2
- 235000008429 bread Nutrition 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- XXDIJWSZFWZBRM-WSKGJZFTSA-N (3z,5e,9e,11z,17e,19e)-8,14,16-trihydroxy-24-methyl-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one Chemical compound CC1CCC\C=C\C=C\C(O)CC(O)C\C=C/C=C/C(O)C\C=C\C=C/C(=O)O1 XXDIJWSZFWZBRM-WSKGJZFTSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 3
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 3
- 101150065749 Churc1 gene Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100038239 Protein Churchill Human genes 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- -1 lactone compounds Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- AVAGQVZSHJYDED-UHFFFAOYSA-N Bakkenolide B Natural products CC(=O)OC1C2C(OC(=O)C(C)=CC)CCC(C)C2(C)CC21C(=C)COC2=O AVAGQVZSHJYDED-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- AVAGQVZSHJYDED-NWAIQIOLSA-N bakkenolide b Chemical compound C([C@]1(C)[C@@H](C)CC[C@@H]([C@@H]1[C@H]1OC(C)=O)OC(=O)C(/C)=C/C)[C@]21C(=C)COC2=O AVAGQVZSHJYDED-NWAIQIOLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明涉及医药技术领域,具体而言,涉及一种毛裂蜂斗菜根茎提取物及其制备方法以及该提取物用于制备治疗和预防肿瘤疾病药物的用途The present invention relates to the technical field of medicine, in particular, to an extract of the rhizome of Butterbur pilaris and its preparation method and the use of the extract for preparing medicines for treating and preventing tumor diseases
背景技术Background technique
毛裂蜂斗菜Petasites tricholobus Franch.属菊科蜂斗菜属植物,其根茎在民间用于解毒祛瘀,外敷治跌打损伤、骨折蛇伤等。为开发利用该植物本发明人对该植物进行了较系统的化学成分及药理研究,曾报道了毛裂蜂斗菜中的四个蜂斗菜内酯新化合物,以及蜂斗菜内酯类化合物用于治疗可能与组胺和/或白三烯有关疾病的用途(专利公开号:CN1844114),但到目前为止,尚未见毛裂蜂斗菜及其提取物有抗肿瘤活性的报道。Petasites tricholobus Franch. belongs to the plant of the genus Butterbur in the Asteraceae family. Its rhizomes are used in the folk for detoxification and blood stasis, and for external application to treat bruises, fractures and snakebites. In order to develop and utilize this plant, the present inventors have carried out systematic chemical composition and pharmacological research on this plant, and have reported four new butterbur lactone compounds and butterbur lactone compounds in Butterbur pilaris It is used to treat diseases that may be related to histamine and/or leukotrienes (patent publication number: CN1844114), but so far, there has been no report that Butterbur pilaris and its extracts have anti-tumor activity.
发明内容Contents of the invention
本发明的目的是提供一种从毛裂蜂斗菜中提取得到的毛裂蜂斗菜提取物及其制备方法,经体外试验,制得的毛裂蜂斗菜提取物,对肝癌、肺癌、宫颈癌、肠癌、肾癌、口腔表皮样癌、乳腺癌肿瘤细胞株有明显的抑制作用,因此,本发明的蜂斗菜提取物可用于治疗肿瘤疾病。这些肿瘤疾病优选包括指肝癌、肺癌、宫颈癌、肠癌、肾癌、口腔表皮样癌、乳腺癌。本发明所制备的毛裂蜂斗菜提取物具有可用于制备抗肿瘤疾病药物的用途。The object of the present invention is to provide a kind of Butterbur pilaris extract that extracts from Butterbur pilaris and preparation method thereof, through in vitro test, the Butterbur pilaris extract that makes has the effect on liver cancer, lung cancer, Cervical cancer, intestinal cancer, kidney cancer, oral epidermoid cancer, breast cancer tumor cell lines have obvious inhibitory effect, therefore, the butterbur extract of the present invention can be used to treat tumor diseases. These tumor diseases preferably include liver cancer, lung cancer, cervical cancer, colon cancer, kidney cancer, oral epidermoid cancer, and breast cancer. The butterbur pilaris extract prepared by the invention has the application of preparing anti-tumor disease medicines.
本发明是通过如下技术方案完成的,具体内容包括:毛裂蜂斗菜提取物的制备以及抗肿瘤药理活性实验。The present invention is accomplished through the following technical solutions, and the specific content includes: the preparation of the extract of the butterbur pilaris and the experiment of antitumor pharmacological activity.
(1)毛裂蜂斗菜提取物的制备(1) Preparation of Butterbur pilaris Extract
本发明毛裂蜂斗菜提取物的制备方法依次由以下步骤组成:The preparation method of the butterbur extract of the present invention consists of the following steps successively:
(1)提取(1) extraction
毛裂蜂斗菜根茎粉碎后,用20-95%的含水乙醇提取得提取液,提取液减压浓缩后离心或过滤,弃沉淀,上清液或过滤液备用;After the rhizome of Butterbur pilaris is crushed, it is extracted with 20-95% aqueous ethanol to obtain an extract, the extract is concentrated under reduced pressure, centrifuged or filtered, the precipitate is discarded, and the supernatant or filtrate is used for later use;
含水乙醇提取的方法为热提、冷浸或渗漉;采用上述方法提取时乙醇的体积用量为生药质量的5-15倍;The method of aqueous ethanol extraction is hot extraction, cold soaking or percolation; when using the above method for extraction, the volume of ethanol used is 5-15 times the mass of crude drug;
(2)吸附洗脱(2) Adsorption and elution
将上述上清液或过滤液进行聚苯乙烯型多孔性吸附树脂吸附、水-50%的含水低级醇淋洗除去杂质后,用上样生药质量的4-12倍量体积的60-95%的含水的C1~C5低级醇洗脱;After the above supernatant or filtrate is subjected to polystyrene-type porous adsorption resin adsorption, and water-50% water-containing lower alcohol to remove impurities, use 60-95% of the volume of 4-12 times the mass of the sample crude drug The aqueous C 1 ~ C 5 lower alcohol elution;
(3)浓缩、干燥(3) Concentration and drying
洗脱液减压浓缩,干燥,即为本发明的毛裂蜂斗菜提取物。The eluate is concentrated under reduced pressure and dried to obtain the Butterbur pilaris extract of the present invention.
将毛裂蜂斗菜的干燥根茎用20~95%乙醇热提或冷浸,提取液浓缩后离心或过滤,取上清液或过滤液进行大孔树脂吸附,先用水-50%的含水低级醇淋洗除去杂质,再用60-95%的含水低级醇洗脱,洗脱液浓缩到至无醇,干燥即为本发明的毛裂蜂斗菜提取物;或将浓缩液通过聚酰胺色谱,依次用水、50%乙醇洗脱,收集50%乙醇洗脱液,浓缩,干燥也可得毛裂蜂斗菜提取物。Heat the dried rhizomes of Butterbur pilaris with 20-95% ethanol or soak them coldly, concentrate the extract, centrifuge or filter, take the supernatant or filtrate for macroporous resin adsorption, first use -50% water-containing low-grade Wash with alcohol to remove impurities, then elute with 60-95% water-containing lower alcohol, concentrate the eluent to no alcohol, and dry it to obtain the extract of Butterbur pilaris of the present invention; or pass the concentrated solution through polyamide chromatography , sequentially eluted with water and 50% ethanol, collected the 50% ethanol eluate, concentrated, and dried to obtain the extract of Butterbur pilaris.
获得的毛裂蜂斗菜提取物成分分析:经反复硅胶柱层析,获得4个量大的化合物,这4个化合物的结构通式如下:Component analysis of the obtained Butterbur pilaris extract: After repeated silica gel column chromatography, 4 compounds with large amounts were obtained. The general structural formulas of these 4 compounds are as follows:
即蜂斗菜内酯D,蜂斗菜内酯B,蜂斗菜内酯IVa,和蜂斗菜内酯IIIa。Namely, butterburide D, butterburide B, butterburide IVa, and butterburide IIIa.
其中:in:
化合物名称 R1 R2 Compound name R 1 R 2
蜂斗菜内酯-D OCOC(CH3)=CHCH3 OCOCH3 Butterbur lactone-D OCOC(CH 3 )=CHCH 3 OCOCH 3
蜂斗菜内酯-B OCOC(CH3)=CHCH3 OCOCH3 Butterbur lactone-B OCOC(CH 3 )=CHCH 3 OCOCH 3
蜂斗菜内酯IVa OCOCH=CHSCH3 OCOCH=C(CH3)2 Butterbur lactone IVa OCOCH=CHSCH 3 OCOCH=C(CH 3 ) 2
蜂斗菜内酯IIIa OCOCH=CHSCH3 OCOC(CH3)=CHCH3 Butterbur lactone IIIa OCOCH=CHSCH 3 OCOC(CH 3 )=CHCH 3
所以,毛裂蜂斗菜提取物主要是蜂斗菜内酯D,蜂斗菜内酯B,蜂斗菜内酯IVa和蜂斗菜内酯IIIa的混合物,经HPLC定量测定,这4个化合物的含量总和占总提取物的50%以上,且蜂斗菜内酯D,蜂斗菜内酯B,蜂斗菜内酯IVa和蜂斗菜内酯IIIa的含量比例为:0.1-5∶0.1-5∶1-9∶1-9。Therefore, the butterbur extract is mainly a mixture of butterbur lactone D, butterbur lactone B, butterbur lactone IVa and butterbur lactone IIIa. Quantitatively determined by HPLC, these 4 compounds The sum of the content of butterbur lactone accounts for more than 50% of the total extract, and the content ratio of butterbur lactone D, butterbur lactone B, butterbur lactone IVa and butterbur lactone IIIa is: 0.1-5:0.1 -5:1-9:1-9.
(2)生物活性试验:受试药物对体外肿瘤细胞生长的抑制作用受试药物:毛裂蜂斗菜提取物(编号为1),蜂斗菜内酯D(编号为2),蜂斗菜内酯B(编号为3),蜂斗菜内酯IVa(编号为4),蜂斗菜内酯IIIa(编号为5)药物配制:将受试药物溶于二甲基亚砜(DMSO)配成储备液,使用时用含10%胎牛血清的RPMI1640细胞培养基稀释100倍。阳性对照药物选择5-氟脲嘧啶(5-FU),配制方法同受试药物。(2) Biological activity test: inhibitory effect of test drugs on tumor cell growth in vitro Test drugs: Butterbur pilaris extract (number 1), butterbur lactone D (number 2), butterbur Lactone B (number 3), butterbur lactone IVa (number 4), butterbur lactone IIIa (number 5) drug preparation: dissolve the test drug in dimethyl sulfoxide (DMSO) The stock solution was diluted 100 times with RPMI1640 cell culture medium containing 10% fetal bovine serum. The positive control drug is 5-fluorouracil (5-FU), and the preparation method is the same as that of the test drug.
肿瘤细胞株:人肺癌细胞A549,人宫颈癌细胞Hela,人大肠癌细胞HCT116,人肝癌细胞HepG2,人肝癌细胞BEL-7402,人肾癌细胞RXF-631L,人口腔表皮样癌细胞KB,人乳腺腺癌细胞MCF-7。Tumor cell lines: human lung cancer cell A549, human cervical cancer cell Hela, human colon cancer cell HCT116, human liver cancer cell HepG2, human liver cancer cell BEL-7402, human kidney cancer cell RXF-631L, human oral epidermoid cancer cell KB, human Breast adenocarcinoma MCF-7.
测定方法:将生长到对数期的各细胞株用胰酶消化,用含10%胎牛血清的RPMI1640培养基制成细胞悬液,以每孔10-4个细胞的浓度接种到96孔细胞培养板上,每孔200μl。24h后,移去培养基,加入含受试药物的培养基,受试药物的终浓度为1×10-3-10μg/ml,5-FU的终浓度为0.01-10μg/ml。对照组中不加受试药物。继续培养3天后,终止培养,用MTT法检测细胞存活率。终止培养前每孔加入MTT溶液(5mg/ml)10μl使MTT终浓度为0.5mg/ml,在37℃,5%CO2的培养箱继续孵育4h后,终止培养,吸去上清液。每孔加入100μl溶解剂(10%SDS,5%异丙醇,0.01M HCl),于37℃下充分溶解,显微镜下观察结晶全部溶解后,在酶标仪上于550nm处测定各孔吸光度(OD)值,计算细胞存活率。细胞存活率(%)=受试药物OD值/对照组OD值×100%。以细胞存活率对剂量对数作图,计算出受试药物对各肿瘤细胞的半数抑制浓度(IC50)。结果:见表1Determination method: Digest each cell line grown to the logarithmic phase with trypsin, make cell suspension with RPMI1640 medium containing 10% fetal bovine serum, inoculate 96-well cells at a concentration of 10-4 cells per well 200 μl per well on the culture plate. After 24 hours, the medium was removed, and the medium containing the test drug was added. The final concentration of the test drug was 1×10 -3 -10 μg/ml, and the final concentration of 5-FU was 0.01-10 μg/ml. No test drug was added to the control group. After continuing to culture for 3 days, the culture was terminated, and the cell viability was detected by MTT method. Before terminating the culture, 10 μl of MTT solution (5 mg/ml) was added to each well to make the final concentration of MTT 0.5 mg/ml. After continuing to incubate for 4 h at 37° C. in an incubator with 5% CO 2 , the culture was terminated and the supernatant was sucked off. Add 100 μl of dissolving agent (10% SDS, 5% isopropanol, 0.01M HCl) to each well, fully dissolve at 37 ° C, observe under a microscope that after the crystals are completely dissolved, measure the absorbance of each well at 550 nm on a microplate reader ( OD) value to calculate cell viability. Cell viability (%)=OD value of the tested drug/OD value of the control group×100%. The cell survival rate was plotted against the dose logarithm, and the half inhibitory concentration (IC 50 ) of the test drug on each tumor cell was calculated. Results: See Table 1
表1受试药物体外抑制肿瘤细胞生长的作用Table 1 The effect of test drugs on inhibiting tumor cell growth in vitro
结果显示受试药物对受试肿瘤细胞都有明显的抑制作用,特别是对于2种肝癌细胞,抑制作用非常明显,作用优于5-FU。结果还显示,毛裂蜂斗菜提取物、蜂斗菜内酯IVa,蜂斗菜内酯IIIa的作用优于蜂斗菜内酯D和蜂斗菜内酯B。The results showed that the tested drugs had obvious inhibitory effects on the tested tumor cells, especially for the two kinds of liver cancer cells, the inhibitory effects were very obvious, and the effect was better than that of 5-FU. The results also showed that butterbur extract, butterbur lactone IVa, butterbur lactone IIIa were more effective than butterbur lactone D and butterbur lactone B.
具体实施方式Detailed ways
下面给出实施例进一步说明本发明但并不构成对本发明的限制。The following examples are given to further illustrate the present invention but are not intended to limit the present invention.
实施例1Example 1
毛裂蜂斗菜干燥根茎用20-95%乙醇加热提取,首次溶媒用量约为生药量的5-10倍,或将毛裂蜂斗菜根茎用20-95%乙醇渗漉提取,溶媒用量为生药量的5-15倍,合并渗漉液,并减压浓缩到一定体积得浓缩液,浓缩液的离心上清液或过滤液通过大孔树脂吸附,(大孔树脂为以苯乙烯为架桥材料的聚苯乙烯型多孔性吸附树脂,如:D101、D201、ZTC-1、AB-8、D4020、860021、HP20、SP825型大孔树脂等),用水-50%的含水乙醇淋洗除去杂质;再用浓度为60-95%的含水低级醇洗脱,低级醇为甲醇、乙醇、或丙醇等C1~C5醇类,其用量为生药量的4-12倍,收集低级醇洗脱液,浓缩至无醇,干燥,即为本发明的毛裂蜂斗菜提取物。Heat the dried rhizomes of Butterbur trichomes with 20-95% ethanol for heating and extraction, and the amount of solvent used for the first time is about 5-10 times of the crude drug amount, or extract the rhizomes of Butterbur trichomes by percolation with 20-95% ethanol, and the dosage of solvents is 5-15 times of the amount of crude drug, combined percolate, and concentrated under reduced pressure to a certain volume to obtain a concentrated solution, the centrifuged supernatant or filtrate of the concentrated solution is adsorbed by a macroporous resin, (the macroporous resin is a frame with styrene Polystyrene type porous adsorption resin of bridge material, such as: D101, D201, ZTC-1, AB-8, D4020, 860021, HP20, SP825 type macroporous resin, etc.), rinse with water-50% aqueous ethanol to remove Impurities; then elute with a water-containing lower alcohol with a concentration of 60-95%. The lower alcohol is C1-C5 alcohols such as methanol, ethanol, or propanol, and its dosage is 4-12 times the crude drug amount. liquid, concentrated to no alcohol, and dried, which is the extract of Butterbur pilaris of the present invention.
实施例2Example 2
毛裂蜂斗菜干燥根茎50公斤,投入渗漉罐,加入250升80%乙醇,浸泡12小时,渗漉,合并渗漉液,并减压浓缩到30升,离心,然后过大孔吸附树脂SP825(北京绿百草公司),用300升40%乙醇淋洗除去杂质;再用300升70%乙醇洗脱,收集洗脱液,减压浓缩后干燥,得本发明的毛裂蜂斗菜提取物0.25公斤。Put 50 kg of dried rhizomes of Butterbur trichomes into a percolation tank, add 250 liters of 80% ethanol, soak for 12 hours, percolate, combine the percolation liquid, concentrate it under reduced pressure to 30 liters, centrifuge, and then pass through the macroporous adsorption resin SP825 (Beijing Lvbaicao Co.), rinsed with 300 liters of 40% ethanol to remove impurities; then eluted with 300 liters of 70% ethanol, collected the eluate, concentrated under reduced pressure and dried to obtain the extract of Butterbur pilaris of the present invention 0.25 kg.
本发明毛裂蜂斗菜提取物的主要活性成分是蜂斗菜内酯D(bakkenolide-D)、蜂斗菜内酯B(bakkenolide-B)、蜂斗菜内酯-IVa(bakkenolide-IIIa)、蜂斗菜内酯(bakkenolide-IIIa),四者的总含量高达50%以上,经体外试验,能有效防治肿瘤,特别是肝癌、肺癌、宫颈癌、肠癌、肾癌、口腔表皮样癌、乳腺癌,所以毛裂蜂斗菜提取物具有可用于制备防治肿瘤药物的用途。The main active ingredients of the butterbur extract of the present invention are butterbur lactone D (bakkenolide-D), butterbur lactone B (bakkenolide-B), butterbur lactone-IVa (bakkenolide-IIIa) , butterbur lactone (bakkenolide-IIIa), the total content of the four is as high as more than 50%. Through in vitro tests, it can effectively prevent and treat tumors, especially liver cancer, lung cancer, cervical cancer, intestinal cancer, kidney cancer, oral epidermoid cancer , breast cancer, so the butterbur pilaris extract can be used to prepare anti-tumor drugs.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100389611A CN101028322B (en) | 2007-04-02 | 2007-04-02 | Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100389611A CN101028322B (en) | 2007-04-02 | 2007-04-02 | Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101028322A CN101028322A (en) | 2007-09-05 |
CN101028322B true CN101028322B (en) | 2011-08-03 |
Family
ID=38713973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100389611A Expired - Fee Related CN101028322B (en) | 2007-04-02 | 2007-04-02 | Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101028322B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020141083A1 (en) * | 2018-12-31 | 2020-07-09 | Max Zeller Soehne Ag | Combination of cimicifuga and petasites extracts for anticancer therapy and prophylaxis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102649783A (en) * | 2011-02-25 | 2012-08-29 | 苏州宝泽堂医药科技有限公司 | Bakkenolide compounds and extraction process thereof |
CN102648927A (en) * | 2011-02-25 | 2012-08-29 | 苏州宝泽堂医药科技有限公司 | Production technology of petasites lactone compound |
CN102846484B (en) * | 2012-04-20 | 2014-04-16 | 朱丹 | Application of Petasites tatewakianus Kitam lactone in preparing anti-ultraviolet compositions |
CN110585255A (en) * | 2016-12-12 | 2019-12-20 | 中国人民解放军第二军医大学 | Application of petasites tricholobus franch extract in preparation of medicines or health-care food for preventing and treating anoxia diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003088985A3 (en) * | 2002-04-22 | 2004-02-26 | Weber & Weber Gmbh & Co Kg | Use of compositions containing petasites for treating diseases |
CN1844114A (en) * | 2006-04-27 | 2006-10-11 | 中国人民解放军第二军医大学 | Butterbur lactone compounds and their application in the field of medicine |
-
2007
- 2007-04-02 CN CN2007100389611A patent/CN101028322B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003088985A3 (en) * | 2002-04-22 | 2004-02-26 | Weber & Weber Gmbh & Co Kg | Use of compositions containing petasites for treating diseases |
CN1844114A (en) * | 2006-04-27 | 2006-10-11 | 中国人民解放军第二军医大学 | Butterbur lactone compounds and their application in the field of medicine |
Non-Patent Citations (2)
Title |
---|
Tian-Shung Wu et al.The bakkenolides from the root of Petasites formosanus and their cytotoxicity.《Chem.Pharm.Bull.》.1999,第47卷(第3期),第375-382页. * |
王玉亮等.毛裂蜂斗菜根茎的化学成分及抗炎活性.《第二军医大学学报》.2006,第27卷(第11期),第1210-1213页. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020141083A1 (en) * | 2018-12-31 | 2020-07-09 | Max Zeller Soehne Ag | Combination of cimicifuga and petasites extracts for anticancer therapy and prophylaxis |
Also Published As
Publication number | Publication date |
---|---|
CN101028322A (en) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102138966B (en) | Tibetan capillaris extract and preparation method, pharmaceutical composition and use thereof | |
CN103599148A (en) | Agriophyllum squarrosum total flavonoid extract, and preparation method and application thereof | |
CN101028322B (en) | Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases | |
CN101289480A (en) | A kind of separation preparation method of liquiritin | |
CN101480422A (en) | Tibetan oriental wormwood extract as well as preparation method and use thereof | |
CN101317883A (en) | Active parts of Prunella vulgaris and its application in the preparation of pharmaceutical compositions | |
CN107854507A (en) | A kind of method that flavones ingredient is extracted from folium artemisiae argyi | |
CN104447910A (en) | Method for preparation of loganin from traditional Chinese medicine Cornus officinalis | |
CN104926773B (en) | Method for extracting flavanone framework compounds in spina gleditsiae and application of flavanone framework compounds | |
CN101062249B (en) | Composition of Anemarrhena extract and Cortex Phellodendri extract and use thereof | |
CN103191143B (en) | New application of cardiac glycoside compound | |
CN103893236B (en) | Preparation method for concentrate of active substances in rape pollen | |
CN115894735A (en) | A kind of eagle tea acidic polysaccharide and its extraction and purification method and anticancer application | |
CN104224952A (en) | Preparation method for total anthraquinones of rheum officinale with stable and uniform proportions of all components | |
CN103239435B (en) | Preparation method of gynura divaricata total caffeoylquinic acid and application in antihyperglycemic agent or health-care product | |
CN107021988B (en) | A kind of red sandalwood alkane glycosides compound that extracts and its extracting method and application in preparation of anti-tumor drugs from the Chinese scholartree of bosom | |
CN102028722A (en) | Extract of effective parts of total saponins in pterocephalus hookeri as well as preparation method and application thereof | |
CN107213176B (en) | A kind of hydrangea leaf extract and its pharmaceutical composition, preparation method and application | |
CN101829080B (en) | Application of iridoid compound to preparation of ovarian cancer resistance medicament | |
CN104398532B (en) | Application of cardiac glycoside compound 12beta-hydroxycalotropin | |
CN105021735B (en) | Detection method of ss and rsMTCA in Nitraria thorn seeds or its extracts | |
CN110251552B (en) | A kind of preparation method of total flavonoids of A. | |
CN104324043B (en) | A kind of purposes of cardiac glycoside compound | |
CN115385978B (en) | Celosia seed compound and preparation method and application thereof | |
CN102423326B (en) | The use of the total flavonoids of bell flower and primrose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110803 Termination date: 20140402 |